Results 21 to 30 of about 250,000 (338)

Screening of Prognostic Factors in Early-Onset Breast Cancer

Technology in Cancer Research & Treatment, 2020
Background: Gene expression profiles from early-onset breast cancer and normal tissues were analyzed to explore the genes and prognostic factors associated with breast cancer.
Zhun Yu MM, Qi He BM, Guoping Xu MM
doaj   +1 more source

PPAR gamma pro12Ala polymorphism and type 2 diabetes: a study in a spanish cohort [PDF]

, 2014
Type 2 diabetes (T2D) is a disease whose occurrence is increasing prevalent in westernized civilizations and is responsible for the proliferation in the morbidity and total mortality of patients with cardiovascular diseases, worldwide.
Cieza Borrella, C, Corral Gudino, L, González Sarmiento, R, Makena Hoghtower, C, Mayoral, R, Miramontes González, JP   +5 more
core   +1 more source

Peroxisome Proliferator-Activated Receptors and Shock State [PDF]

The Scientific World JOURNAL, 2006
Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone receptor superfamily of ligand-activated transcription factors that are related to retinoid, steroid, and thyroid hormone receptors. Three isotypes of PPARs have been identified: alpha, beta/delta, and gamma, encoded by different genes and distributed in various ...
ESPOSITO, EMANUELA, CUZZOCREA, Salvatore, MELI R.   +2 more
openaire   +5 more sources

The pathophysiological function of peroxisome proliferator-activated receptor-γ in lung-related diseases

Respiratory Research, 2005
Research into respiratory diseases has reached a critical stage and the introduction of novel therapies is essential in combating these debilitating conditions.
Lin Diana, Kota Bhavani, Razmovski-Naumovski Valentina, Huang Tom, Roufogalis Basil D   +4 more
doaj   +1 more source

Peroxisome Proliferator-Activated Receptor alpha (PPAR alpha) down-regulation in cystic fibrosis lymphocytes [PDF]

, 2006
Background: PPARs exhibit anti-inflammatory capacities and are potential modulators of the inflammatory response. We hypothesized that their expression and/or function may be altered in cystic fibrosis (CF), a disorder characterized by an excessive host ...
C Hubeau, RB Moss, P Reineck, AA Ionescu, LS Nixon, ME Poynter, P Delerive, SW Chung, BM Forman, W Wahli, JD Tugwood, JM Shipley, A Madej, JP Despres, N Marx, B Staels, Z Israelian-Konaraki, A Trifilieff, MA Birrell, M Roulet, PM Farrell, AP Sampson, JT Zakrzewski, J Carlstedt-Duke, SD Freedman, SM Loitsch, KA Kreuzer, JL Su, JD Dignam, TP Dean, K Balough, TZ Khan, A Augarten, F Akbiyik, I Inoue, DC Jones, P Greally, E Dagli, TA Waldmann, JH Parmentier, K Beier, C Andersson, M Ollero, H Pall, G Chinetti, PR Devchand, N Marx, AE Lovett-Racke, A Linden, F McAllister, RB Moss, RB Moss, C Hubeau, RU Sorensen   +53 more
core   +1 more source

The case for intraocular delivery of PPAR agonists in the treatment of diabetic retinopathy

BMC Ophthalmology, 2012
Background Systemic therapeutics targeting the peroxisome proliferator-activated receptors have been found to be beneficial in the treatment of diabetic retinopathy.
Treacy Maxwell P, Hurst Tara P
doaj   +1 more source

Balaglitazone reverses P-glycoprotein-mediated multidrug resistance via upregulation of PTEN in a PPARγ-dependent manner in leukemia cells

Tumor Biology, 2017
Multidrug resistance in tumor cells is still a big challenge in cancer treatment. Therefore, identification ofsafe and effective multidrug resistance–reversing compounds with minimal side effects is an important approach in cancer treatment.
Bahman Yousefi, Ako Azimi, Maryam Majidinia, Vahid Shafiei-Irannejad, Reza Badalzadeh, Behzad Baradaran, Nosratollah Zarghami, Nasser Samadi   +7 more
doaj   +1 more source

Hepatic peroxisome proliferator-activated receptor γ and α-mRNA expression in HCV-infected adults is decreased by HIV co-infection and is also affected by ethnicity

Clinics, 2015
OBJECTIVE: To determine peroxisome proliferator activated receptor α and γ mRNA expression in liver tissue of hepatitis C virus-infected patients with and without human immunodeficiency virus and its possible contribution to an acceleration of liver ...
Nathan J. Shores, Maria Cássia Mendes-Corrêa, Ivana Maida, JoLyn Turner, Kevin P. High, Sergio Babudieri, Marina Núãez   +6 more
doaj   +1 more source

Sleeping Beauty screen reveals Pparg activation in metastatic prostate cancer [PDF]

, 2016
Prostate cancer (CaP) is the most common adult male cancer in the developed world. The paucity of biomarkers to predict prostate tumor biology makes it important to identify key pathways that confer poor prognosis and guide potential targeted therapy ...
Adams, David J., Ahmad, Imran, Edwards, Joanne, Galbraith, Laura, Hedley, Ann, Leung, Hing Y., Loveridge, Carolyn, Markert, Elke, Mui, Ernest, Patel, Rachana, Repiscak, Peter, Rust, Alistair G., Salji, Mark, Sansom, Owen J., Tan, Ee Hong, van der Weyden, Louise   +15 more
core   +1 more source

Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.

Gastroenterology, 2016
BACKGROUND & AIMS Elafibranor is an agonist of the peroxisome proliferator-activated receptor-α and peroxisome proliferator-activated receptor-δ. Elafibranor improves insulin sensitivity, glucose homeostasis, and lipid metabolism and reduces inflammation.
V. Ratziu, S. Harrison, S. Francque, P. Bedossa, P. Lehert, L. Serfaty, M. Romero‐Gomez, J. Boursier, M. Abdelmalek, S. Caldwell, J. Drenth, Q. Anstee, D. Hum, Rémy Hanf, A. Roudot, S. Megnien, B. Staels, A. Sanyal   +17 more
semanticscholar   +1 more source